Loading

Perspective Open Access
Volume 5 | Issue 2 | DOI: https://doi.org/10.33696/cardiology.5.055

Investigating the Hormetic Role of Resolvin D2 in Atherosclerotic Cardiovascular Disease: Pathways to Biomarker Recognition for Resolvins?

  • 1Master of Medical Sciences in Clinical Investigation, Harvard Medical School, Boston, MA 02115, USA
  • 2Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
+ Affiliations - Affiliations

Corresponding Author

Loukman Omarjee, loukman_omarjee@hms.harvard.edu

Received Date: April 19, 2024

Accepted Date: May 28, 2024

Abstract

Introduction: Resolvin D2 (RvD2), a mediator that helps resolve inflammation, plays a role in stopping the progression of atherosclerotic cardiovascular disease (ASCVD). Understanding how RvD2 levels relate to ASCVD risk could reveal its potential as both a treatment target and a biomarker.

Methods: We examined the research by Liu et al., which used an analytical method that combined restricted cubic splines with multivariable Cox proportional hazard models. This approach aimed to uncover the link between plasma RvD2 levels and ASCVD risk considering linear patterns. The study also examined how serum cholesterol might influence this relationship through sensitivity analyses.

Results: Liu et al. discovered an inverted U-shaped relationship between plasma RvD2 levels and ASCVD risk. They found that while high levels of RvD2 are protective, moderate levels could raise the risk of ASCVD. Additionally, the study suggested that serum cholesterol might play a mediating role in this connection.

Conclusion: These results indicate that the dynamics of RvD2 levels in relation to ASCVD risk are intricate and challenge conventional views on how inflammation resolves in heart health. The study emphasizes the importance of exploring the basis for this threshold effect occurrence and how RvD2 could serve as a biomarker for ASCVD.

Further studies should explore conducting long-term research, including randomized controlled trials, to confirm the effectiveness and safety of using RvD2 as a treatment option.

Keywords

Resolvin D2, Inflammation resolution, Specialized pro-resolving mediator, Biomarkers, Atherosclerotic Cardiovascular disease, ASCVD

Author Information X